Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Regulatory Functions of Natural Killer Cells in Multiple Sclerosis.

Gross CC, Schulte-Mecklenbeck A, Wiendl H, Marcenaro E, Kerlero de Rosbo N, Uccelli A, Laroni A.

Front Immunol. 2016 Dec 19;7:606. doi: 10.3389/fimmu.2016.00606. eCollection 2016. Review.

2.

Frequency and phenotype of natural killer cells and natural killer cell subsets in bovine lymphoid compartments and blood.

Hamilton CA, Mahan S, Bell CR, Villarreal-Ramos B, Charleston B, Entrican G, Hope JC.

Immunology. 2017 May;151(1):89-97. doi: 10.1111/imm.12708. Epub 2017 Feb 7.

3.

The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases.

Mao-Draayer Y, Sarazin J, Fox D, Schiopu E.

Clin Immunol. 2017 Feb;175:10-15. doi: 10.1016/j.clim.2016.11.008. Epub 2016 Nov 23. Review.

PMID:
27890706
4.
5.

Human Circulating and Tissue-Resident CD56(bright) Natural Killer Cell Populations.

Melsen JE, Lugthart G, Lankester AC, Schilham MW.

Front Immunol. 2016 Jun 30;7:262. doi: 10.3389/fimmu.2016.00262. eCollection 2016. Review.

6.

Critical Role of the Sphingolipid Pathway in Stroke: a Review of Current Utility and Potential Therapeutic Targets.

Sun N, Keep RF, Hua Y, Xi G.

Transl Stroke Res. 2016 Oct;7(5):420-38. doi: 10.1007/s12975-016-0477-3. Epub 2016 Jun 24. Review.

PMID:
27339463
7.

Sphingosine-1-Phosphate Signaling in Immune Cells and Inflammation: Roles and Therapeutic Potential.

Aoki M, Aoki H, Ramanathan R, Hait NC, Takabe K.

Mediators Inflamm. 2016;2016:8606878. doi: 10.1155/2016/8606878. Epub 2016 Feb 7. Review. Erratum in: Mediators Inflamm. 2016;2016:2856829.

8.

The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism.

Yang H, Brackett CM, Morales-Tirado VM, Li Z, Zhang Q, Wilson MW, Benjamin C, Harris W, Waller EK, Gudkov AV, Burdelya LG, Grossniklaus HE.

Oncotarget. 2016 Jan 19;7(3):2936-50. doi: 10.18632/oncotarget.6500.

9.

Exit Strategies: S1P Signaling and T Cell Migration.

Baeyens A, Fang V, Chen C, Schwab SR.

Trends Immunol. 2015 Dec;36(12):778-87. doi: 10.1016/j.it.2015.10.005. Review.

10.

Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism.

Kwong E, Li Y, Hylemon PB, Zhou H.

Acta Pharm Sin B. 2015 Mar;5(2):151-7. doi: 10.1016/j.apsb.2014.12.009. Epub 2015 Feb 9. Review.

11.

Terminal NK cell maturation is controlled by concerted actions of T-bet and Zeb2 and is essential for melanoma rejection.

van Helden MJ, Goossens S, Daussy C, Mathieu AL, Faure F, Marçais A, Vandamme N, Farla N, Mayol K, Viel S, Degouve S, Debien E, Seuntjens E, Conidi A, Chaix J, Mangeot P, de Bernard S, Buffat L, Haigh JJ, Huylebroeck D, Lambrecht BN, Berx G, Walzer T.

J Exp Med. 2015 Nov 16;212(12):2015-25. doi: 10.1084/jem.20150809. Epub 2015 Oct 26.

12.

Oxysterols and EBI2 promote osteoclast precursor migration to bone surfaces and regulate bone mass homeostasis.

Nevius E, Pinho F, Dhodapkar M, Jin H, Nadrah K, Horowitz MC, Kikuta J, Ishii M, Pereira JP.

J Exp Med. 2015 Oct 19;212(11):1931-46. doi: 10.1084/jem.20150088. Epub 2015 Oct 5.

13.

CCR2 inhibition sequesters multiple subsets of leukocytes in the bone marrow.

Fujimura N, Xu B, Dalman J, Deng H, Aoyama K, Dalman RL.

Sci Rep. 2015 Jul 24;5:11664. doi: 10.1038/srep11664.

14.

Immune dysfunction in Niemann-Pick disease type C.

Platt N, Speak AO, Colaco A, Gray J, Smith DA, Williams IM, Wallom KL, Platt FM.

J Neurochem. 2016 Jan;136 Suppl 1:74-80. doi: 10.1111/jnc.13138. Epub 2015 Jun 4. Review.

15.

Analysis of sphingosine kinase activity in single natural killer cells from peripheral blood.

Dickinson AJ, Meyer M, Pawlak EA, Gomez S, Jaspers I, Allbritton NL.

Integr Biol (Camb). 2015 Apr;7(4):392-401. doi: 10.1039/c5ib00007f.

16.

PTEN regulates natural killer cell trafficking in vivo.

Leong JW, Schneider SE, Sullivan RP, Parikh BA, Anthony BA, Singh A, Jewell BA, Schappe T, Wagner JA, Link DC, Yokoyama WM, Fehniger TA.

Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):E700-9. doi: 10.1073/pnas.1413886112. Epub 2015 Feb 2.

17.

Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo.

El-Sherbiny YM, Holmes TD, Wetherill LF, Black EV, Wilson EB, Phillips SL, Scott GB, Adair RA, Dave R, Scott KJ, Morgan RS, Coffey M, Toogood GJ, Melcher AA, Cook GP.

Clin Exp Immunol. 2015 Apr;180(1):98-107. doi: 10.1111/cei.12562.

18.

CXCR4 and a cell-extrinsic mechanism control immature B lymphocyte egress from bone marrow.

Beck TC, Gomes AC, Cyster JG, Pereira JP.

J Exp Med. 2014 Dec 15;211(13):2567-81. doi: 10.1084/jem.20140457. Epub 2014 Nov 17.

19.

TOX2 regulates human natural killer cell development by controlling T-BET expression.

Vong QP, Leung WH, Houston J, Li Y, Rooney B, Holladay M, Oostendorp RA, Leung W.

Blood. 2014 Dec 18;124(26):3905-13. doi: 10.1182/blood-2014-06-582965. Epub 2014 Oct 28.

20.

ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile.

Yamamoto R, Okada Y, Hirose J, Koshika T, Kawato Y, Maeda M, Saito R, Hattori K, Harada H, Nagasaka Y, Morokata T.

PLoS One. 2014 Oct 27;9(10):e110819. doi: 10.1371/journal.pone.0110819. eCollection 2014.

Supplemental Content

Support Center